Billets de Michelle Dawson

Billet publié sur Twitter/X le 29/03/2022 06:13

Retour aux billets Billet précédent Billet suivant
Twitter/X Essai clinique clinicaltrials.gov Extrait cité dans le billet Question posée par Dawson dans le billet Lien intégré au billet Termes sur l’autisme
Ouvrir le billet original

Infos sur le lien intégré au billet

Essai clinique

Joanne Kurtzberg, MD, The Marcus Foundation (2022). hCT-MSC Infusion in Adults With Autism Spectrum Disorder. ClinicalTrials.gov. Joanne Kurtzberg, MD.

Plus d’infos

Liens cités structurés

1 ressource citée

Essai clinique Récupéré Publication clinicaltrials.gov

Joanne Kurtzberg, MD, The Marcus Foundation (2022). hCT-MSC Infusion in Adults With Autism Spectrum Disorder. ClinicalTrials.gov. Joanne Kurtzberg, MD.

Date de publication
24/01/2022
Identifiant
NCT04484077
Auteurs
Joanne Kurtzberg, MD, The Marcus Foundation
Source
ClinicalTrials.gov
Type de référence
clinical_trial
Éditeur
Joanne Kurtzberg, MD
Source de métadonnées
clinicaltrials.gov

Résumé

The purpose of the study is to determine the safety and tolerability of a single intravenous dose of Human Umbilical Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC) in adults with autism spectrum disorder (ASD). hCT-MSC is a cell product isolated from umbilical cord tissue. The cells from the cord tissue are processed and expanded in the laboratory and then infused intravenously in a single dose per participant. Participants will be ages 18-35 years, with ASD and a full-scale IQ \>70 without an identified genetic cause of autism. Participants will have an in-person baseline visit and remote follow up visits at 6 and 12 months. In addition to the primary endpoints evaluating safety, the study will evaluate changes in social communications skills after hCT-MSC administration.

Ouvrir la source